PRECIGEN, INC. Annual Report - How They Did This Year

I’ve reviewed the 2025 filings for Precigen to help you understand where the company stands as we head into 2026.

1. What does this company do?

Precigen is a biotech firm focused on gene and cell therapies. Instead of traditional pills, they engineer cells to treat complex diseases. The company is currently shifting from a research-focused business to a commercial one. Their primary focus is Papzimeos (PRGN-2012), an immunotherapy for recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV. They have received FDA Fast Track designation and are pursuing Accelerated Approval.

2. Financial Performance: The "Report Card"

Precigen is in a high-stakes transition. They currently spend significantly more on research and development (R&D) than they earn from sales.

• The Big Shift: In 2025, the company brought in $48.2 million, mostly from licensing deals. However, they spent $78.5 million on R&D to push PRGN-2012 through clinical trials.
• Profitability: The company reported a loss of $112.4 million in 2025. Management is currently working to cut operating costs by 15% by closing manufacturing facilities and streamlining their program portfolio.

3. Financial Health: Keeping the Lights On

For a biotech company, cash management is the most critical indicator of longevity.

• Cash Position: As of December 31, 2025, Precigen held $62.8 million in cash.
• Burn Rate: The company spent approximately $22 million per quarter in 2025. To extend their runway through 2027, they raised $35 million through share offerings in the second half of the year.
• Market Value: By mid-2025, the market valued the company at $219.4 million. Investors should note that issuing new shares to raise capital can dilute the ownership percentage of existing shareholders.

4. Major Wins and Challenges

• The Commercial Pivot: The company is scaling its UltraCAR-T platform and building a specialized sales team to reach the 15,000 to 20,000 RRP patients in the U.S.
• Strategic Focus: They sold their Trans Ova Genetics subsidiary, generating $15 million to fund their core oncology pipeline.
• Customer Concentration: A notable risk is that 60% of their revenue is tied to a single collaboration. The stability of this contract is vital for funding ongoing clinical trials.

5. Future Outlook and Risks

The company’s future is heavily tied to the success of Papzimeos.

• Regulatory Risk: The FDA holds the final say on the company's timeline. They are currently in discussions regarding trial designs for PRGN-2012. Any regulatory delays in 2026 would likely necessitate additional capital raises to cover ongoing operational costs.
• Funding Risk: Because the company is not yet profitable, they rely on the equity markets for survival. Future share issuances remain a possibility if clinical or commercial milestones are delayed.

The Bottom Line: Precigen is a high-stakes bet on science. They are currently in the "show me the money" phase. If Papzimeos wins FDA approval, the company’s financial profile could shift significantly. If it fails, the company will face increased pressure to either secure a buyer or implement further aggressive cost-cutting measures. Before investing, consider whether your risk tolerance aligns with a company that is entirely dependent on the outcome of a single clinical program.